Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 13/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.39 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.39 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4619925 | 0.80 | S1PR1 (0.59) | S1PR1S1PR3 | |
| SCHEMBL29151626 | 0.78 | S1PR1 (0.51) | S1PR1NOTUMS1PR4S1PR3S1PR5 | |
| SCHEMBL4619354 | 0.78 | S1PR1 (0.49) | S1PR1S1PR3 | |
| SCHEMBL29151634 | 0.77 | S1PR1 (0.58) | S1PR1S1PR4S1PR3S1PR5 | |
| SCHEMBL29151616 | 0.76 | S1PR1 (0.47) | S1PR1NOTUMS1PR4S1PR3S1PR5 | |
| SCHEMBL29151637 | 0.73 | S1PR1 (0.55) | S1PR1S1PR4S1PR3S1PR5 | |
| SCHEMBL29151651 | 0.73 | S1PR1 (0.58) | S1PR1S1PR4S1PR3S1PR5 | |
| SCHEMBL29151646 | 0.72 | S1PR1 (0.58) | S1PR1S1PR4S1PR3S1PR5 | |
| SCHEMBL29151621 | 0.72 | S1PR1 (0.53) | S1PR1S1PR4S1PR3S1PR5 | |
| SCHEMBL29151622 | 0.71 | S1PR1 (0.60) | S1PR1S1PR4S1PR3S1PR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080306124-A1 | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands | NOVARTIS AG (CH) | 2008-12-11 | — | — | US | disclosed |
| US-20080306124-A1 | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands | NOVARTIS AG (CH) | 2008-12-11 | — | — | US | disclosed |
| US-20080306124-A1 | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands | NOVARTIS AG (CH) | 2008-12-11 | — | — | US | disclosed |
| EP-1893591-A1 | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS | Novartis AG (CH) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006131336-A1 | POLYCYCLIC OXADIAZOLES OR I SOXAZOLES AND THEIR USE AS SlP RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2006-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080306124-A1 | Polycyclic Oxadiazoles or I Soxazoles and Their Use as Sip Receptor Ligands | SOX18, SIGMAR1, SUCNR1 | S1PR1 13/4885PTGS2 1915/4885PTGS1 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.